References
- Furst DE, Keystone EC, Fleischmann R, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis 2010;69(Suppl. 1):i2-29
- Enbrel (etanercept) Prescribing Information. Thousand Oaks, CA: Immunex Corporation, 2007
- Humira (adalimumab) Prescribing Information. North Chicago, IL: Abbott Laboratories, 2007
- Remicade (infliximab) Prescribing Information. Malvern, PA: Centocor, Inc., 2006
- Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther 2002;24:1720-40
- Sidiropoulos P, Boumpas D. Differential drug resistance to anti-tumor necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis 2006;65:701-3
- Haraoui B, Cameron L, Ouellet M, et al. Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. J Rheumatol 2006;33:31-6
- Ariza-Ariza R, Navarro-Sarabia F, Hernandez-Cruz B, et al. Dose escalation of the anti-TNF-α agents in patients with rheumatoid arthritis. A systematic review. Rheumatology 2007;46:529-32
- Berger A, Edelsberg J, Li TT, et al. Dose intensification with infliximab in patients with rheumatoid arthritis. Ann Pharmacother 2005;39:2021-5
- Bullano MF, McNeeley BJ, Yu YF, et al. Comparison of costs associated with the use of etanercept, infliximab, and adalimumab for the treatment of rheumatoid arthritis. Manag Care Interface 2006;19:47-53
- Abarca J, Malone DC, Armstrong EP, et al. Longitudinal analysis of the use of etanercept versus infliximab determined from medical chart audit. J Manag Care Pharm 2004;10:538-42
- Gilbert TD Jr, Smith D, Ollendorf DA. Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord 2004;5:36
- van Vollenhoven RF, Brannemark S, Klareskog L. Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect. Ann Rheum Dis 2004;63:426-30
- Ollendorf DA, Massrotti E, Birbara C, et al. Frequency, predictors, and economic impact of upward dose adjustment of infliximab in managed care patients with rheumatoid arthritis. J Manag Care Pharm 2005;11:383-93
- Harley CR, Frytak R, Tandon N. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etancercept, or methotrexate. Am J Manag Care 2003;9(Suppl. 6):136-43
- Chapter 8, Cohort Studies. In: Greenberg RS, Daniels S, Flanders WD, Eley JW, Boring JR (eds.) Medical Epidemiology. Norwalk, CT: Appleton & Lange, 1993:89-132
- Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987;40:373-83
- SAS Institute Inc., Cary, NC, USA. SAS version 9.1.3